{"id":406,"date":"2021-09-16T08:28:51","date_gmt":"2021-09-16T15:28:51","guid":{"rendered":"https:\/\/derm-biomepharmaceuticals.com\/?p=406"},"modified":"2021-09-16T08:32:30","modified_gmt":"2021-09-16T15:32:30","slug":"derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d","status":"publish","type":"post","link":"https:\/\/derm-biomepharmaceuticals.com\/ch\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/","title":{"rendered":"Derm-Biome Pharmaceuticals, Inc. \u62a5\u544a\u7279\u5e94\u6027\u76ae\u708e\u4e34\u5e8a\u524d\u7814\u7a76\u7684\u79ef\u6781\u7ed3\u679c\uff1a\u5176\u65b0\u4e00\u4ee3\u5316\u5408\u7269\u660e\u663e\u6bd4 FDA \u6279\u51c6\u7684\u5916\u7528 AD \u836f\u7269 crisaborole \u66f4\u6709\u6548"},"content":{"rendered":"

\u4e0d\u5217\u98a0\u54e5\u4f26\u6bd4\u4e9a\u7701\u6e29\u54e5\u534e\uff0c2021 \u5e74 9 \u6708 16 \u65e5\uff08\u73af\u7403\u901a\u8baf\u793e\uff09\u2014 Derm-Biome Pharmaceuticals, Inc \u662f\u4e00\u5bb6\u603b\u90e8\u4f4d\u4e8e\u6e29\u54e5\u534e\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u4e13\u6ce8\u4e8e\u76ae\u80a4\u5065\u5eb7\u548c\u5065\u5eb7\u8001\u9f84\u5316\uff0c\u5f88\u9ad8\u5174\u5730\u5ba3\u5e03\uff0c\u5176\u4e24\u79cd\u5916\u7528\u836f\u7269\u5bf9\u76ae\u80a4\u5065\u5eb7\u4ea7\u751f\u4e86\u663e\u7740\u7684\u6291\u5236\u4f5c\u7528\u3002\u4e00\u79cd\u5b8c\u5584\u7684\u7279\u5e94\u6027\u76ae\u708e\uff08AD\uff09\u5c0f\u9f20\u6a21\u578b\u3002 AD \u662f\u4e00\u79cd\u6162\u6027\u708e\u75c7\u6027\u76ae\u80a4\u75c5\uff0c\u5176\u9700\u6c42\u672a\u5f97\u5230\u6ee1\u8db3\uff0c\u901a\u5e38\u4e0e\u6291\u90c1\u75c7\u548c\u751f\u6d3b\u8d28\u91cf\u4e0b\u964d\u6709\u5173\u3002\u6700\u8fd1\u53d1\u5e03\u7684\u7814\u7a76\u62a5\u544a\u4f30\u8ba1\uff0c\u5230 2026 \u5e74\uff0c\u5168\u7403 AD \u6cbb\u7597\u5e02\u573a\u5c06\u9ad8\u8fbe $340 \u4ebf\u7f8e\u5143\u3002<\/p>\n

\u4e0d\u5217\u98a0\u54e5\u4f26\u6bd4\u4e9a\u5927\u5b66\u76ae\u80a4\u75c5\u5b66\u6559\u6388\u3001\u6e29\u54e5\u534e\u6cbf\u6d77\u5065\u5eb7\u7814\u7a76\u6240\u76ae\u80a4\u7814\u7a76\u9879\u76ee\u4e3b\u4efb\u5468\u53cb\u6587\u535a\u58eb\u8868\u793a\uff1a\u201c\u7279\u5e94\u6027\u76ae\u708e\u662f\u4e00\u79cd\u5267\u70c8\u7619\u75d2\u7684\u708e\u75c7\u6027\u76ae\u80a4\u75c5\uff0c\u7ed9\u5168\u4e16\u754c\u6570\u767e\u4e07\u4eba\u5e26\u6765\u8eab\u5fc3\u75db\u82e6\u3002\u76ee\u524d\u53ef\u7528\u7684\u7597\u6cd5\uff0c\u5305\u62ec FDA \u6700\u8fd1\u6279\u51c6\u7684\u836f\u7269 Crisaborole\uff0c\u7531\u4e8e\u6709\u6548\u6027\u6216\u8010\u53d7\u6027\u7684\u9650\u5236\u800c\u4e0d\u80fd\u4ee4\u4eba\u6ee1\u610f\u3002\u56e0\u6b64\uff0c\u4ee4\u4eba\u5174\u594b\u7684\u662f\u53d1\u73b0 Derm-Biome \u65b0\u5f00\u53d1\u7684\u51e0\u79cd\u5316\u5408\u7269\u5728\u963b\u6b62\u7279\u5e94\u6027\u76ae\u708e\u5c0f\u9f20\u6a21\u578b\u4e2d\u76ae\u80a4\u708e\u75c7\u7684\u53d1\u5c55\u65b9\u9762\u8fdc\u8fdc\u4f18\u4e8e crisaborole\u3002\u5982\u679c\u5728\u8fdb\u4e00\u6b65\u7684\u5b9e\u9a8c\u6d4b\u8bd5\u4e2d\u5f97\u5230\u8bc1\u5b9e\uff0c\u8fd9\u4e9b\u5316\u5408\u7269\u5177\u6709\u6210\u4e3a\u6cbb\u7597\u7279\u5e94\u6027\u76ae\u708e\u7684\u4e0b\u4e00\u4ee3\u7597\u6cd5\u7684\u5de8\u5927\u6f5c\u529b\u201d\u3002<\/p>\n

\u8fd9\u4e9b\u65b0\u578b\u5316\u5408\u7269\u5df2\u4e8e 2021 \u5e74 6 \u6708 14 \u65e5\u63d0\u4ea4\uff0c\u9898\u4e3a\u201c\u6cbb\u7597\u708e\u75c7\u6027\u76ae\u80a4\u75c5\u7684\u7ec4\u5408\u7269\u548c\u65b9\u6cd5\u201d\u7684\u7f8e\u56fd\u4e13\u5229\u7533\u8bf7\u3002<\/p>\n

Derm-Biome \u9996\u5e2d\u6267\u884c\u5b98 Gordon Eberwein\uff1a\u201c\u6211\u4eec\u5bf9\u8fd9\u6b21\u8bd5\u9a8c\u7684\u7ed3\u679c\u611f\u5230\u975e\u5e38\u5174\u594b\u3002\u6211\u4eec\u5df2\u7ecf\u83b7\u5f97\u4e86\u4e00\u79cd\u6709\u524d\u9014\u7684\u76ae\u80a4\u75c5\u5019\u9009\u836f\u7269\uff0c\u4f46\u6211\u4eec\u51b3\u5b9a\u5f00\u53d1\u65b0\u4e00\u4ee3\u65b0\u578b\u884d\u751f\u7269\uff0c\u5e0c\u671b\u521b\u9020\u51fa\u66f4\u5177\u6d3b\u6027\u548c\u53ef\u6eb6\u6027\u7684\u5316\u5408\u7269\u3002\u6211\u4eec\u73b0\u5728\u76f8\u4fe1\uff0c\u6211\u4eec\u62e5\u6709\u4e00\u79cd\u5546\u4e1a\u4e0a\u53ef\u884c\u7684\u5019\u9009\u836f\u7269\uff0c\u53ef\u4ee5\u6539\u5584\u6162\u6027\u708e\u75c7\u6027\u76ae\u80a4\u75c5\u60a3\u8005\u7684\u751f\u6d3b\u3002\u201d<\/p>\n

Derm-Biome CSO Poul Sorensen \u535a\u58eb\uff1a\u201c\u6211\u4eec\u5bf9\u6700\u8fd1\u7684\u53d1\u73b0\u611f\u5230\u975e\u5e38\u5174\u594b\uff0c\u6211\u4eec\u7684\u5316\u5408\u7269\u5728\u975e\u5e38\u5b8c\u5584\u7684\u7279\u5e94\u6027\u76ae\u708e\u5c0f\u9f20\u6a21\u578b\u4e2d\u975e\u5e38\u6709\u6548\u3002\u4f5c\u4e3a\u4e00\u540d\u5bf9\u5206\u5b50\u7597\u6cd5\u957f\u671f\u611f\u5174\u8da3\u7684\u751f\u7269\u533b\u5b66\u7814\u7a76\u4eba\u5458\uff0c\u6211\u53ef\u4ee5\u660e\u786e\u5730\u8bf4\uff0c\u8fd9\u79cd\u620f\u5267\u6027\u7684\u4f53\u5185\u7ed3\u679c\u6781\u5176\u7f55\u89c1\u3002\u201d<\/p>\n

\u9884\u8ba1\u5c06\u4e8e 2022 \u5e74\u7b2c\u4e00\u5b63\u5ea6\u5411\u52a0\u62ff\u5927\u536b\u751f\u90e8\u63d0\u4ea4\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7 (CTA)\u3002<\/p>\n

\u5173\u4e8e Derm-Biome \u5236\u836f\u516c\u53f8<\/p>\n

Derm-Biome Pharmaceuticals, Inc. \u662f\u4e00\u5bb6\u4e34\u5e8a\u524d\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u62e5\u6709\u4e00\u7cfb\u5217\u81f4\u529b\u4e8e\u6539\u5584\u76ae\u80a4\u5065\u5eb7\u548c\u5065\u5eb7\u8870\u8001\u7684\u5929\u7136\u5316\u5408\u7269\u884d\u751f\u7269\u3002\u6211\u4eec\u7684\u5316\u5408\u7269\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5e76\u5177\u6709\u65b0\u9896\u7684\u6297\u708e\u3001\u6297\u83cc\u3001\u6297\u6c27\u5316\u548c\u6297\u80bf\u7624\u7279\u6027\u3002<\/p>\n

\u63a5\u89e6
\n\u6295\u8d44\u8005\u67e5\u8be2\uff1a
\n\u6208\u767b\u00b7\u827e\u4f2f\u6e29
\ngeberwein@derm-biome.com
\nhttps:\/\/derm-biomepharmaceuticals.com\/<\/p>","protected":false},"excerpt":{"rendered":"

… <\/p>","protected":false},"author":2,"featured_media":408,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent-news"],"yoast_head":"\nDerm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/derm-biomepharmaceuticals.com\/ch\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"og:description\" content=\"...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/derm-biomepharmaceuticals.com\/ch\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\" \/>\n<meta property=\"og:site_name\" content=\"Derm-Biome Pharmaceuticals Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-16T15:28:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-16T15:32:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"539\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Derm-Biome Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Derm-Biome Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\"},\"author\":{\"name\":\"Derm-Biome Admin\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\"},\"headline\":\"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole\",\"datePublished\":\"2021-09-16T15:28:51+00:00\",\"dateModified\":\"2021-09-16T15:32:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\"},\"wordCount\":450,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg\",\"articleSection\":[\"Recent News\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\",\"name\":\"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg\",\"datePublished\":\"2021-09-16T15:28:51+00:00\",\"dateModified\":\"2021-09-16T15:32:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg\",\"width\":1000,\"height\":539},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/derm-biomepharmaceuticals.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#website\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"name\":\"Derm-Biome Pharmaceuticals Inc.\",\"description\":\"Startup Biopharmaceutical Company\",\"publisher\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#organization\",\"name\":\"Derm-Biome Pharmaceuticals\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"contentUrl\":\"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png\",\"width\":450,\"height\":200,\"caption\":\"Derm-Biome Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d\",\"name\":\"Derm-Biome Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g\",\"caption\":\"Derm-Biome Admin\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/derm-biomepharmaceuticals.com\/ch\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/","og_locale":"zh_CN","og_type":"article","og_title":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.","og_description":"...","og_url":"https:\/\/derm-biomepharmaceuticals.com\/ch\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/","og_site_name":"Derm-Biome Pharmaceuticals Inc.","article_published_time":"2021-09-16T15:28:51+00:00","article_modified_time":"2021-09-16T15:32:30+00:00","og_image":[{"width":1000,"height":539,"url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg","type":"image\/jpeg"}],"author":"Derm-Biome Admin","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"Derm-Biome Admin","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"2 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#article","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/"},"author":{"name":"Derm-Biome Admin","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d"},"headline":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole","datePublished":"2021-09-16T15:28:51+00:00","dateModified":"2021-09-16T15:32:30+00:00","mainEntityOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/"},"wordCount":450,"commentCount":0,"publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg","articleSection":["Recent News"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/","url":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/","name":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole - Derm-Biome Pharmaceuticals Inc.","isPartOf":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage"},"thumbnailUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg","datePublished":"2021-09-16T15:28:51+00:00","dateModified":"2021-09-16T15:32:30+00:00","breadcrumb":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#primaryimage","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2021\/09\/announcement-2021-sept.jpg","width":1000,"height":539},{"@type":"BreadcrumbList","@id":"https:\/\/derm-biomepharmaceuticals.com\/derm-biome-pharmaceuticals-inc-reports-positive-results-from-a-preclinical-study-in-atopic-dermatitis-its-new-generation-of-compounds-are-significantly-more-effective-than-fda-approved-topical-ad-d\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/derm-biomepharmaceuticals.com\/"},{"@type":"ListItem","position":2,"name":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole"}]},{"@type":"WebSite","@id":"https:\/\/derm-biomepharmaceuticals.com\/#website","url":"https:\/\/derm-biomepharmaceuticals.com\/","name":"Derm-Biome Pharmaceuticals Inc.","description":"Startup Biopharmaceutical Company","publisher":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/derm-biomepharmaceuticals.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/derm-biomepharmaceuticals.com\/#organization","name":"Derm-Biome Pharmaceuticals","url":"https:\/\/derm-biomepharmaceuticals.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/","url":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","contentUrl":"https:\/\/derm-biomepharmaceuticals.com\/wp-content\/uploads\/2019\/01\/Derm-Biome-Pharmaceuticals-white-1.png","width":450,"height":200,"caption":"Derm-Biome Pharmaceuticals"},"image":{"@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/7fd946a95040e8683129145f79976d8d","name":"Derm-Biome Admin","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/derm-biomepharmaceuticals.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/010b14acf7a9fd5e8fbbc766302fccb7?s=96&d=mm&r=g","caption":"Derm-Biome Admin"}}]}},"_links":{"self":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/posts\/406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/comments?post=406"}],"version-history":[{"count":2,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/posts\/406\/revisions"}],"predecessor-version":[{"id":410,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/posts\/406\/revisions\/410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/media\/408"}],"wp:attachment":[{"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/media?parent=406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/categories?post=406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/derm-biomepharmaceuticals.com\/ch\/wp-json\/wp\/v2\/tags?post=406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}